申请人:ChemoCentryx, Inc.
公开号:US20140057937A1
公开(公告)日:2014-02-27
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
提供了作为CCR1受体的强效拮抗剂的化合物,并具有体内抗炎活性。这些化合物通常是芳基哌嗪衍生物,可用于制药组合物、治疗CCR1介导疾病的方法,以及作为竞争性CCR1拮抗剂鉴定的控制物。